Is Johnson & Johnson (JNJ) a Good Stock to Buy before Earnings?
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
In fact, this unit grew by about 4.2% in Q1 and continues to benefit from strong sales of cancer treatment Darzalex as well as Tremfya, which grew by 20%. In addition, new filings with the FDA, including pediatric use for Stelara and additional CNS therapies, indicate that the firm has a healthy pipeline going forward. Meanwhile, the MedTech division, which includes devices and surgical technology, grew by 4.1%. It is worth noting that this unit has faced pricing pressure in China, but recent acquisitions like Abiomed and Shockwave could help revive sales in 2025.
As investors look ahead to the report, key things to watch include the company's full-year guidance to see whether J&J will reaffirm its revenue outlook of around $91–91.8 billion and EPS range of $10.50–$10.70. Investors should also focus on how the company is managing costs, especially with MedTech facing about $400 million in tariff exposure and the upcoming biosimilar competition for top drugs like Stelara. Lastly, any updates on drug approvals, product launches, or how J&J plans to integrate new biotech acquisitions could offer insights into long-term growth.
Options Traders Anticipate a Large Move
Using TipRanks' Options tool, we can see what options traders are expecting from the stock immediately after its earnings report. The expected earnings move is determined by calculating the at-the-money straddle of the options closest to expiration after the earnings announcement. If this sounds complicated, don't worry, the Options tool does this for you. Indeed, it currently says that options traders are expecting a 2.6% move in either direction.
Is JNJ Stock a Good Buy?
Turning to Wall Street, analysts have a Moderate Buy consensus rating on JNJ stock based on seven Buys, nine Holds, and zero Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average JNJ price target of $173.47 per share implies 10.6% upside potential.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Waters, BD biosciences unit agree to $17.5B merger
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Waters has agreed to combine with BD's biosciences and diagnostic solutions business in a deal valued at about $17.5 billion, the companies said Monday. The combined company will continue to operate under the Waters name and retain its listing on the New York Stock Exchange. The BD business will be spun off generally tax-free to BD shareholders and simultaneously merged with a subsidiary of Waters, through a structure known as a Reverse Morris Trust. Waters CEO Udit Batra will lead the new entity, and Waters' headquarters will remain in Milford, Massachusetts. The transaction doubles Waters' total addressable market to about $40 billion, with an annual growth rate of 5% to 7%, according to the statement. Waters shares fell more than 11% to $313.66 in early NYSE trading on Monday, while BD shares were down about 1% at $174.12. BD in February revealed its intention to separate the biosciences and diagnostics business, which generated $3.4 billion in revenue in BD's 2024 financial year. The merger with Waters creates a combined company with expected 2025 sales of about $6.5 billion. Under the agreement, BD shareholders will own about 39.2% of the combined company and Waters the other 60.8%. BD will also receive a cash distribution of about $4 billion before the combination is completed. Waters is expected to assume approximately $4 billion of debt. Waters will acquire both the flow cytometry and the microbiology business of BD, Leerink Partners analyst Puneet Souda said in a report to clients. 'Though BD's flow cytometry is [a] uniquely differentiated and leading business, we don't expect investors to view the deal attractively in the near-term given the dilution and now higher exposure to microbiology,' Souda wrote. Jefferies analyst Tycho Peterson said he expected Waters shares to trade lower due to the deal size and other variables, but longer term saw merits to the transaction including the ability to create scale and an attractive margin profile. The deal is expected to close near the end of the first quarter of calendar year 2026, subject to regulatory approvals, Waters shareholder approval and other closing conditions. Jeff Jonas, portfolio manager at Gabelli Funds, said the merger does not put too much debt on the combined company, which will allow smaller dealmaking to continue. 'It's a good fit for Waters that gets them closer to Thermo Fisher and Danaher in terms of size and scale,' Jonas said in an email. Recommended Reading BD plans split from life science business to fuel medtech investment Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Zimmer agrees to distribute Getinge products to expand ASC offering
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Zimmer Biomet has struck a deal to distribute Getinge's infection control and surgical portfolio to its ambulatory surgery center customers, the companies said Thursday. The agreement positions ASCs, facilities that provide same-day surgical care, to source implants, surgical robotics, surgical equipment, lighting and other products from a single company. Zimmer initially plans to target the U.S. before potentially expanding to other parts of the world as it ramps up efforts to grow its ASC business. Zimmer and other orthopedic companies have identified ASCs as a growth opportunity. Interest has risen as the number of ASCs has grown and Medicare reimbursement has expanded. There were almost 6,500 Medicare-certified ASCs in the U.S. as of March 2025, compared to just over 6,000 in late 2022, according to the Ambulatory Surgery Center Association. Medicare began covering total knee replacements in 2020 and total hip replacements in 2021. ASCs account for around 20% of Zimmer's U.S. sales, CEO Ivan Tornos said on an earnings call in May, up from 2% to 4% before the COVID-19 pandemic. The company forecasts that ASCs will account for 40% to 60% of sales in the next five years. Zimmer has struck deals to try to exceed the market growth rate. Partnering with Getinge could support Zimmer's ambitions by expanding its offering to ASC customers beyond orthopedic implants and surgical robotics. Jehanzeb Noor, chief strategy, innovation and business development officer at Zimmer, outlined the thinking behind the deal in a statement. 'As orthopedic surgeries increasingly migrate from traditional hospital settings to ASCs, the imperative to drive efficiency, enhance patient safety and improve clinical outcomes has never been greater,' Noor said. 'By aligning with Getinge, we're accelerating our ability to support surgeons in advancing these priorities, while shaping the future of orthopedic care.' The agreement comes about six months after Zimmer disclosed a deal to buy foot and ankle implant provider Paragon 28 for $1.1 billion. Talking at a Goldman Sachs event in June, Tornos said the Paragon 28 deal would enable cross-selling of trauma and biologic devices and give Zimmer 'a better category leadership position in ASC.' Tornos said there were 'more deals to come that are similar to Paragon 28.' Recommended Reading Zimmer touts ASC opportunity with Paragon 28 purchase Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
Wolfe Research Affirms Outperform Rating on Johnson & Johnson (JNJ) on Improving Fundamentals
Johnson & Johnson (NYSE:JNJ) is one of Goldman Sachs' top healthcare stock picks. On July 10, analysts at Wolfe Research reiterated an 'Outperform' rating on the stock and a $175 price target. The bullish stance underscores the company's strong performance year to date amid soaring regulatory concerns. Gil C/ The stock is up by more than 8% year-to-date, outperforming the S&P 500, which is up by approximately 6%. The research firm expects the stock to continue its impressive run, especially with the settling of the talc litigation in the third quarter. An update on the litigation should alleviate concerns and mitigate the long-term impact on the stock. In addition, Wolfe Research is bullish on Johnson & Johnson, as the estimated $400 million tariff impact is poised to be reduced by half. The company is on course to deliver $22.8 billion in revenues in the second quarter, in line with consensus estimates. Full-year revenues are expected at $91.9 billion, slightly above consensus estimates of $91.4 billion. Strong performance in Tremfya and Darzalex is expected to continue offsetting the slowdown in Stelara's sales growth. Johnson & Johnson (NYSE:JNJ) is a healthcare company focused on developing and producing pharmaceutical products and medical devices. It develops and delivers innovative medicines to treat a range of diseases, including oncology, immunology, neuroscience, and cardiopulmonary conditions. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Green Energy Penny Stocks to Buy Right Now and 10 Most Popular AI Penny Stocks to Buy According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
